184
Participants
Start Date
August 24, 2022
Primary Completion Date
August 28, 2028
Study Completion Date
August 28, 2028
Tarlatamab
Tarlatamab will be administered as an intravenous (IV) infusion.
Carboplatin
Carboplatin will be administered as an intravenous (IV) infusion.
Etoposide
Etoposide will be administered as an intravenous (IV) infusion.
Atezolizumab
Atezolizumab will be administered as an intravenous (IV) infusion.
Durvalumab
Durvalumab will be administered as an intravenous (IV) infusion.
Chris OBrien Lifehouse, Camperdown
Rigshospitalet, Copenhagen
Universitair Ziekenhuis Antwerpen, Edegem
Inselspital Bern, Bern
Jessa Ziekenhuis - Campus Virga Jesse, Hasselt
Universitaetsspital Basel, Basel
AZ Delta Campus Rumbeke, Roeselare
Algemeen Ziekenhuis Maria Middelares, Ghent
National Taiwan University Hospital, Taipei
New York University Grossman School of Medicine and New York University Langone Hospitals, New York
Taipei Veterans General Hospital, Taipei
Christiana Care Health Services, Newark
Fondazione IRCCS San Gerardo dei Tintori, Monza (MB)
West Virginia University Health Sciences Center, Morgantown
The University of North Carolina at Chapel Hill, Chapel Hill
Hospital Universitario 12 de Octubre, Madrid
Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec, Saint-Herblain
Universitaetsklinikum Essen, Essen
Henry Ford Health System, Detroit
Avera Cancer Institute, Sioux Falls
Centre Leon Berard, Lyon
National Cheng Kung University Hospital, Tainan City
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Azienda Ospedaliera Universitaria Renato Dulbecco, Catanzaro
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles
Gustave Roussy, Villejuif
Swedish Cancer Institute Medical Oncology, Seattle
Rambam Medical Center, Haifa
Rabin Medical Center, Petah Tikva
Sheba Medical Center, Ramat Gan
Hadassah Ein-Kerem Medical Center, Jerusalem
Rutgers Cancer Institute of New Jersey, New Brunswick
Princess Margaret Cancer Centre, Toronto
CHU de Quebec Hopital de l Enfant Jesus, Québec
Universitaetsklinikum Dresden, Dresden
Istituto Nazionale Tumori Regina Elena, Rome
National Cancer Center Hospital East, Kashiwa-shi
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku
Universitair Medisch Centrum Groningen, Groningen
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Universitari Vall d Hebron, Barcelona
Lead Sponsor
Amgen
INDUSTRY